BD Announced Application of CE Mark for the Liverty TIPS Stent Graft

Why It Matters

CE marking unlocks a major European market for BD’s innovative TIPS solution, potentially improving outcomes for millions with portal hypertension and expanding the interventional radiology portfolio. The data debut at SIR will shape clinical adoption and set a benchmark for adjustable‑diameter shunts.

Key Takeaways

• CE Mark granted for Liverty TIPS Stent Graft in EU
• Adjustable 6–10 mm diameter expands personalized portal hypertension therapy
• ARCH trial results to debut at SIR Annual Meeting April 2026
• Device features nitinol frame and dual‑layer ePTFE with carbon coating
• US use remains limited to investigational trials only

Pulse Analysis

Portal hypertension, a common complication of cirrhosis, affects an estimated 58 million patients worldwide and drives high‑cost hospitalizations. Transjugular intrahepatic portosystemic shunt (TIPS) procedures relieve elevated portal pressure, yet traditional stents offer limited sizing flexibility, often leading to suboptimal flow dynamics. BD’s Liverty TIPS Stent Graft addresses this gap with a 6–10 mm adjustable inner diameter and a broad selection of covered lengths, enabling clinicians to tailor shunt dimensions to individual vascular anatomy. The device’s nitinol frame and dual‑layer ePTFE with carbon‑impregnated inner surface promise enhanced durability and reduced thrombosis risk, positioning it as a next‑generation solution in the interventional toolkit.

The pivotal ARCH trial, a global, prospective, multi‑center study, evaluated safety and efficacy of the adjustable‑diameter graft in real‑world settings. Preliminary results, slated for presentation at the Society of Interventional Radiology’s April 2026 meeting, are expected to provide the first robust evidence on calibrated small‑diameter TIPS outcomes. Early data suggest improved control of portal pressure, fewer post‑procedure complications, and better long‑term patency compared with fixed‑diameter alternatives. Such findings could shift clinical guidelines toward personalized shunt sizing, reinforcing the value proposition of adjustable devices in complex liver disease management.

Securing CE Mark approval marks a critical regulatory milestone, granting BD access to the EU’s €500 billion medical‑device market. While the graft remains investigational in the United States, the European launch offers a platform for post‑market surveillance and real‑world evidence generation. Successful adoption in Europe may accelerate FDA discussions, potentially expanding the device’s footprint globally. For investors and industry observers, BD’s move underscores a broader trend toward customizable, data‑driven interventional solutions that align with precision‑medicine objectives.